DM4 is a cytotoxic agent. It is used as the cytotoxic component in antibody-drug conjugates.
Structure of 799840-96-3
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
NCT Number | Condition Or Disease | Phase | Start Date | Sponsor | Status |
---|---|---|---|---|---|
NCT03045393 | Breast Cancer Triple Negative | Phase 1 | 2018-07-05 | Duke University | Withdrawn (Inadequate enrollment) |
NCT04606914 | Ovarian Cancer | Phase 2 | 2021-07-08 | University of Alabama at Birmingham | Recruiting |
NCT05041257 | Ovarian Cancer | Phase 2 | 2021-09-22 | ImmunoGen, Inc. | Recruiting |
NCT03455556 | Mesothelin Positive | Phase 1 | 2020-05-15 | Mayo Clinic | Terminated (slow accrual) |
NCT00352131 | Non-colorectal Cancer | Phase 1 | 2010-03-17 | ImmunoGen, Inc. | Completed |
Maytansinoid DM4 is a semi-synthetic derivative of Maytansine and a widely used ADC cytotoxin in the development of antibody-drug conjugates. As a potent ADC payload, DM4 acts as a tubulin polymerization inhibitor, disrupting microtubule dynamics, arresting cell division, and ultimately inducing apoptosis. Its structural modifications compared to Maytansine enhance its conjugation compatibility with linker technologies, making it a versatile payload for targeted oncology therapeutics.
Within the ADC platform, Maytansinoid DM4 is commonly conjugated to antibodies through cleavable disulfide linkers. This strategy enables efficient drug release inside tumor cells where the reductive environment triggers cleavage, liberating the active cytotoxin. Such a mechanism ensures that DM4 exerts its potent cytotoxic effects selectively at the tumor site while minimizing damage to healthy tissues. The balance of stability in circulation and controlled intracellular release highlights DM4 as a reliable payload choice for next-generation ADC development.
Applications of Maytansinoid DM4 include its integration into clinical-stage ADC candidates for the treatment of various cancers, such as breast cancer, ovarian cancer, and hematologic malignancies. Its high potency allows effective therapeutic outcomes even at low drug-to-antibody ratios, which is essential for maintaining a favorable therapeutic index. Moreover, DM4’s chemical flexibility enables researchers to design customized linker-payload systems optimized for stability, pharmacokinetics, and tumor selectivity, expanding the scope of ADC drug discovery.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01351 | Maytansinoid B | 1628543-40-7 |
What is Maytansinoid DM4?
Maytansinoid DM4 is a potent microtubule-disrupting cytotoxin commonly used in the construction of antibody-drug conjugates (ADCs). It binds to tubulin and inhibits microtubule assembly, making it highly effective for targeted delivery in cancer therapy research.
3/9/2018
Dear team, how does Maytansinoid DM4 function in ADCs?
In ADCs, Maytansinoid DM4 serves as the payload that exerts cytotoxic activity upon internalization by target cells. Once released intracellularly, it disrupts microtubules, leading to cell cycle arrest and apoptosis. This mechanism ensures selective action on targeted cells.
12/9/2016
Good afternoon! What types of linkers are compatible with Maytansinoid DM4?
Maytansinoid DM4 is compatible with a variety of cleavable and non-cleavable linkers, including disulfide and thioether-based linkers. The choice of linker influences drug release kinetics, stability, and overall efficacy of the resulting ADC.
9/12/2019
Dear Sir, I would like to know if BOC Sciences can provide custom Maytansinoid DM4 ADC synthesis.
BOC Sciences offers custom ADC synthesis incorporating Maytansinoid DM4. Our services include linker selection, conjugation optimization, and analytical characterization to support research and preclinical development.
9/3/2019
Good afternoon! How is Maytansinoid DM4 supplied for research purposes?
Maytansinoid DM4 is provided in formats suitable for laboratory use, including solid or solution forms, along with handling guidelines to ensure safe storage, accurate dosing, and compatibility with ADC development workflows.
4/7/2022
— Dr. David Miller, Senior ADC Researcher (USA)
Maytansinoid DM4 delivered by BOC Sciences met all our purity and stability requirements. Technical support was very helpful.
9/12/2019
— Dr. Alice Johnson, Medicinal Chemist (UK)
Excellent consistency between Maytansinoid DM4 batches enabled smooth ADC conjugation and in vivo studies.
4/7/2022
— Dr. Felix Schneider, Biochemist (Germany)
Fast delivery and professional support. Maytansinoid DM4 quality was outstanding.
9/3/2019
— Dr. Sophie Wilson, Senior Scientist (Canada)
Detailed QC reports ensured confidence in every batch of Maytansinoid DM4.
3/9/2018
— Dr. Robert Hughes, Research Fellow (USA)
BOC Sciences’ Maytansinoid DM4 helped accelerate our ADC pipeline efficiently.
— Dr. Emma Laurent, Pharmacology Scientist (France)
Excellent technical guidance and consistent Maytansinoid DM4 quality. Crucial for our projects.
12/9/2016
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.